Summary
Sales of Novo Nordisk's Wegovy pill were kr5.39 billion, up 53% from Q2 and above the kr4.62 billion forecast in the company-compiled consensus.
Novo Nordisk’s Wegovy pill beats forecasts as it battles Lilly
Source & full coverage: this summary is aggregated from Free Malaysia Today Business, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at Free Malaysia Today Business →
